{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:21:08Z","timestamp":1761920468287,"version":"3.37.3"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2018,5,16]],"date-time":"2018-05-16T00:00:00Z","timestamp":1526428800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Study was supported by an investigator initiated grant from Teva Pharmaceuticals, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s40263-018-0521-9","type":"journal-article","created":{"date-parts":[[2018,5,16]],"date-time":"2018-05-16T08:27:47Z","timestamp":1526459267000},"page":"763-770","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["The Effect of Glatiramer Acetate on Retinal Nerve Fiber Layer Thickness in Patients with Relapsing\u2013Remitting Multiple Sclerosis: A Longitudinal Optical Coherence Tomography Study"],"prefix":"10.1007","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7799-1485","authenticated-orcid":false,"given":"Robert","family":"Zivadinov","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleonora","family":"Tavazzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesper","family":"Hagemeier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen","family":"Carl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Hojnacki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Channa","family":"Kolb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bianca","family":"Weinstock-Guttman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,5,16]]},"reference":[{"issue":"7","key":"521_CR1","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1080\/14737175.2016.1181543","volume":"16","author":"R Zivadinov","year":"2016","unstructured":"Zivadinov R, et al. Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine. Expert Rev Neurother. 2016;16(7):777\u201393.","journal-title":"Expert Rev Neurother"},{"issue":"7","key":"521_CR2","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1212\/WNL.45.7.1268","volume":"45","author":"KP Johnson","year":"1995","unstructured":"Johnson KP, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1995;45(7):1268\u201376.","journal-title":"Neurology"},{"issue":"3","key":"521_CR3","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1002\/ana.64","volume":"49","author":"G Comi","year":"2001","unstructured":"Comi G, Filippi M, Wolinsky JS. European\/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging\u2013measured disease activity and burden in patients with relapsing multiple sclerosis. European\/Canadian Glatiramer Acetate Study Group. Ann Neurol. 2001;49(3):290\u20137.","journal-title":"Ann Neurol"},{"issue":"6","key":"521_CR4","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1002\/ana.23938","volume":"73","author":"O Khan","year":"2013","unstructured":"Khan O, et al. Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. Ann Neurol. 2013;73(6):705\u201313.","journal-title":"Ann Neurol"},{"issue":"7","key":"521_CR5","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1007\/s00415-013-6903-5","volume":"260","author":"DL Arnold","year":"2013","unstructured":"Arnold DL, Narayanan S, Antel S. Neuroprotection with glatiramer acetate: evidence from the PreCISe trial. J Neurol. 2013;260(7):1901\u20136.","journal-title":"J Neurol"},{"issue":"1","key":"521_CR6","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.pathophys.2010.04.007","volume":"18","author":"R Zivadinov","year":"2011","unstructured":"Zivadinov R, et al. Glatiramer acetate recovers microscopic tissue damage in patients with multiple sclerosis. A case-control diffusion imaging study. Pathophysiology. 2011;18(1):61\u20138.","journal-title":"Pathophysiology"},{"issue":"6","key":"521_CR7","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1191\/1352458505ms1234oa","volume":"11","author":"O Khan","year":"2005","unstructured":"Khan O, et al. Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis. Mult Scler. 2005;11(6):646\u201351.","journal-title":"Mult Scler"},{"issue":"7","key":"521_CR8","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1007\/s00415-016-8127-y","volume":"263","author":"LJ Balk","year":"2016","unstructured":"Balk LJ, et al. Timing of retinal neuronal and axonal loss in MS: a longitudinal OCT study. J Neurol. 2016;263(7):1323\u201331.","journal-title":"J Neurol"},{"issue":"4","key":"521_CR9","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s11940-017-0452-7","volume":"19","author":"AU Brandt","year":"2017","unstructured":"Brandt AU, et al. Monitoring the course of MS with optical coherence tomography. Curr Treat Options Neurol. 2017;19(4):15.","journal-title":"Curr Treat Options Neurol"},{"issue":"1\u20132","key":"521_CR10","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jns.2007.10.020","volume":"268","author":"E Grazioli","year":"2008","unstructured":"Grazioli E, et al. Retinal nerve fiber layer thickness is associated with brain MRI outcomes in multiple sclerosis. J Neurol Sci. 2008;268(1\u20132):12\u20137.","journal-title":"J Neurol Sci"},{"issue":"7","key":"521_CR11","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1080\/14737175.2016.1180978","volume":"16","author":"S Gupta","year":"2016","unstructured":"Gupta S, et al. Optical coherence tomography and neurodegeneration: are eyes the windows to the brain? Expert Rev Neurother. 2016;16(7):765\u201375.","journal-title":"Expert Rev Neurother"},{"issue":"6","key":"521_CR12","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1212\/WNL.0000000000003582","volume":"88","author":"J Button","year":"2017","unstructured":"Button J, et al. Disease-modifying therapies modulate retinal atrophy in multiple sclerosis: a retrospective study. Neurology. 2017;88(6):525\u201332.","journal-title":"Neurology"},{"issue":"2","key":"521_CR13","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/ana.22366","volume":"69","author":"CH Polman","year":"2011","unstructured":"Polman CH, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292\u2013302.","journal-title":"Ann Neurol"},{"issue":"4","key":"521_CR14","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1212\/WNL.46.4.907","volume":"46","author":"FD Lublin","year":"1996","unstructured":"Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 1996;46(4):907\u201311.","journal-title":"Neurology"},{"issue":"3","key":"521_CR15","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1148\/radiol.2016160060","volume":"281","author":"R Zivadinov","year":"2016","unstructured":"Zivadinov R, et al. Cerebral microbleeds in multiple sclerosis evaluated on susceptibility-weighted images and quantitative susceptibility maps: a case\u2013control study. Radiology. 2016;281(3):884\u201395.","journal-title":"Radiology"},{"issue":"4","key":"521_CR16","doi-asserted-by":"publisher","first-page":"e34823","DOI":"10.1371\/journal.pone.0034823","volume":"7","author":"P Tewarie","year":"2012","unstructured":"Tewarie P, et al. The OSCAR-IB consensus criteria for retinal OCT quality assessment. PLoS One. 2012;7(4):e34823.","journal-title":"PLoS One"},{"issue":"8","key":"521_CR17","doi-asserted-by":"publisher","first-page":"1137-e61","DOI":"10.1111\/ene.12449","volume":"21","author":"R Zivadinov","year":"2014","unstructured":"Zivadinov R, et al. Retinal nerve fiber layer thickness and thalamus pathology in multiple sclerosis patients. Eur J Neurol. 2014;21(8):1137-e61.","journal-title":"Eur J Neurol"},{"issue":"7","key":"521_CR18","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1177\/1352458510371640","volume":"16","author":"SB Syc","year":"2010","unstructured":"Syc SB, et al. Reproducibility of high-resolution optical coherence tomography in multiple sclerosis. Mult Scler. 2010;16(7):829\u201339.","journal-title":"Mult Scler"},{"key":"521_CR19","isbn-type":"print","volume-title":"A practical guide using statistical software","author":"B West","year":"2006","unstructured":"West B, Welch K, Galecki A. A practical guide using statistical software. London: Chapman & Hall\/CRC; 2006. ISBN 978-1-584-88480-4.","ISBN":"https:\/\/id.crossref.org\/isbn\/9781584884804"},{"issue":"2","key":"521_CR20","doi-asserted-by":"publisher","first-page":"e0172120","DOI":"10.1371\/journal.pone.0172120","volume":"12","author":"R Behbehani","year":"2017","unstructured":"Behbehani R, et al. Optical coherence tomography segmentation analysis in relapsing remitting versus progressive multiple sclerosis. PLoS One. 2017;12(2):e0172120.","journal-title":"PLoS One"},{"issue":"11","key":"521_CR21","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1136\/bjo.2010.199232","volume":"95","author":"E Garcia-Martin","year":"2011","unstructured":"Garcia-Martin E, et al. Risk factors for progressive axonal degeneration of the retinal nerve fibre layer in multiple sclerosis patients. Br J Ophthalmol. 2011;95(11):1577\u201382.","journal-title":"Br J Ophthalmol"},{"issue":"11","key":"521_CR22","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1007\/s00415-016-8271-4","volume":"263","author":"NK Ayoubi El","year":"2016","unstructured":"El Ayoubi NK, et al. Retinal measures correlate with cognitive and physical disability in early multiple sclerosis. J Neurol. 2016;263(11):2287\u201395.","journal-title":"J Neurol"},{"issue":"Pt 6","key":"521_CR23","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1093\/brain\/awq080","volume":"133","author":"AJ Green","year":"2010","unstructured":"Green AJ, et al. Ocular pathology in multiple sclerosis: retinal atrophy and inflammation irrespective of disease duration. Brain. 2010;133(Pt 6):1591\u2013601.","journal-title":"Brain"},{"issue":"8","key":"521_CR24","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1001\/archneurol.2009.107","volume":"66","author":"DS Reich","year":"2009","unstructured":"Reich DS, et al. Damage to the optic radiation in multiple sclerosis is associated with retinal injury and visual disability. Arch Neurol. 2009;66(8):998\u20131006.","journal-title":"Arch Neurol"},{"issue":"1","key":"521_CR25","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1212\/WNL.0b013e31827b1a1c","volume":"80","author":"JN Ratchford","year":"2013","unstructured":"Ratchford JN, et al. Active MS is associated with accelerated retinal ganglion cell\/inner plexiform layer thinning. Neurology. 2013;80(1):47\u201354.","journal-title":"Neurology"},{"issue":"5","key":"521_CR26","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.autrev.2012.09.005","volume":"12","author":"R Aharoni","year":"2013","unstructured":"Aharoni R. The mechanism of action of glatiramer acetate in multiple sclerosis and beyond. Autoimmun Rev. 2013;12(5):543\u201353.","journal-title":"Autoimmun Rev"},{"key":"521_CR27","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.clim.2017.06.006","volume":"181","author":"M Spadaro","year":"2017","unstructured":"Spadaro M, et al. Biological activity of glatiramer acetate on Treg and anti-inflammatory monocytes persists for more than 10\u00a0years in responder multiple sclerosis patients. Clin Immunol. 2017;181:83\u20138.","journal-title":"Clin Immunol"},{"issue":"3","key":"521_CR28","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s12035-007-8002-z","volume":"36","author":"R Arnon","year":"2007","unstructured":"Arnon R, Aharoni R. Neurogenesis and neuroprotection in the CNS\u2013fundamental elements in the effect of Glatiramer acetate on treatment of autoimmune neurological disorders. Mol Neurobiol. 2007;36(3):245\u201353.","journal-title":"Mol Neurobiol"},{"issue":"7","key":"521_CR29","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1177\/1352458508090221","volume":"14","author":"J Toledo","year":"2008","unstructured":"Toledo J, et al. Retinal nerve fiber layer atrophy is associated with physical and cognitive disability in multiple sclerosis. Mult Scler. 2008;14(7):906\u201312.","journal-title":"Mult Scler"},{"issue":"16","key":"521_CR30","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1212\/01.wnl.0000295995.46586.ae","volume":"69","author":"E Gordon-Lipkin","year":"2007","unstructured":"Gordon-Lipkin E, et al. Retinal nerve fiber layer is associated with brain atrophy in multiple sclerosis. Neurology. 2007;69(16):1603\u20139.","journal-title":"Neurology"},{"issue":"2","key":"521_CR31","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.nic.2016.12.004","volume":"27","author":"M Filippi","year":"2017","unstructured":"Filippi M, Preziosa P, Rocca MA. Microstructural MR imaging techniques in multiple sclerosis. Neuroimaging Clin N Am. 2017;27(2):313\u201333.","journal-title":"Neuroimaging Clin N Am"},{"issue":"4","key":"521_CR32","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1177\/135245859900500415","volume":"5","author":"F Barkhof","year":"1999","unstructured":"Barkhof F. MRI in multiple sclerosis: correlation with expanded disability status scale (EDSS). Mult Scler. 1999;5(4):283\u20136.","journal-title":"Mult Scler"},{"issue":"10","key":"521_CR33","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1007\/s00415-012-6475-9","volume":"259","author":"K Hackmack","year":"2012","unstructured":"Hackmack K, et al. Can we overcome the \u2018clinico-radiological paradox\u2019 in multiple sclerosis? J Neurol. 2012;259(10):2151\u201360.","journal-title":"J Neurol"},{"issue":"5","key":"521_CR34","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1002\/ana.24487","volume":"78","author":"S Saidha","year":"2015","unstructured":"Saidha S, et al. Optical coherence tomography reflects brain atrophy in multiple sclerosis: a four-year study. Ann Neurol. 2015;78(5):801\u201313.","journal-title":"Ann Neurol"},{"key":"521_CR35","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1212\/WNL.0000000000004736","volume":"89","author":"M Pisa","year":"2017","unstructured":"Pisa M, et al. No evidence of disease activity is associated with reduced rate of axonal retinal atrophy in MS. Neurology. 2017;89:2469\u201375.","journal-title":"Neurology."},{"issue":"7","key":"521_CR36","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1177\/1352458510397414","volume":"17","author":"E Garcia-Martin","year":"2011","unstructured":"Garcia-Martin E, et al. Effect of optic neuritis on progressive axonal damage in multiple sclerosis patients. Mult Scler. 2011;17(7):830\u20137.","journal-title":"Mult Scler"},{"issue":"10","key":"521_CR37","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S1474-4422(17)30278-8","volume":"16","author":"A Petzold","year":"2017","unstructured":"Petzold A, et al. Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis. Lancet Neurol. 2017;16(10):797\u2013812.","journal-title":"Lancet Neurol"},{"issue":"24","key":"521_CR38","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1212\/WNL.0000000000002774","volume":"86","author":"A Cruz-Herranz","year":"2016","unstructured":"Cruz-Herranz A, et al. The APOSTEL recommendations for reporting quantitative optical coherence tomography studies. Neurology. 2016;86(24):2303\u20139.","journal-title":"Neurology"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-018-0521-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-018-0521-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-018-0521-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,15]],"date-time":"2019-05-15T21:17:45Z","timestamp":1557955065000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-018-0521-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,16]]},"references-count":38,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["521"],"URL":"https:\/\/doi.org\/10.1007\/s40263-018-0521-9","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"type":"print","value":"1172-7047"},{"type":"electronic","value":"1179-1934"}],"subject":[],"published":{"date-parts":[[2018,5,16]]},"assertion":[{"value":"16 May 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This study was supported by an investigator-initiated grant from Teva Pharmaceuticals, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Robert Zivadinov received personal compensation from EMD Serono, Genzyme-Sanofi, Claret Medical, Celgene, and Novartis for speaking and consultant fees. He received financial support for research activities from Teva Pharmaceuticals, Biogen, Genzyme-Sanofi, Novartis, Claret Medical, Intekrin-Coherus, Protembis, and IMS Health. Eleonora Tavazzi, Jesper Hagemeier, and Ellen Carl have nothing to disclose. Channa Kolb has received speaker honoraria and consultant fees from EMD Serono, Teva Pharmaceuticals, Acorda, Novartis, Genzyme, and Biogen-Idec. David Hojnacki has received speaker honoraria and consultant fees from Biogen-Idec, Teva Pharmaceutical Industries Ltd., EMD Serono, Pfizer Inc., and Novartis. Bianca Weinstock- Guttman received honoraria as a speaker and as a consultant for Biogen Idec, Teva Pharmaceuticals, EMD Serono, Sanofi Genzyme, Novartis, and Acorda. Dr Weinstock-Guttman received research funds from Biogen Idec, Teva Pharmaceuticals, EMD Serono, Sanofi Genzyme, Novartis, and Acorda.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}